0

Dr. Meletis CBD Book Chapters 1-6

By June 17, 2020CBD, Dr. Meletis

Chapter 1

What Is The Endocannabinoid System and Why Should You Care About It?

 

By Chris D. Meletis, N.D.

 

To keep your mind healthy, your joints strong, your mood calm, and your digestive system comfortable, your body was given an amazing tool. That tool is called the endocannabinoid system. Researchers discovered its existence only as recently as 1988, when they were investigating how cannabinoids found in the marijuana plant (Cannabis sativa) affect the body.

 

The interesting thing about this system is that you don’t need marijuana to activate it. It’s a perfectly natural pathway that has served humankind and other mammals for millennia. Your body makes its own cannabinoids that work through this same system. These cannabinoids that your body makes are called endocannabinoids. There are also hemp-based cannabinoids (phytocannabinoids)—such as cannabidiol (CBD)—that work through the endocannabinoid system. These phytocannabinoids can even increase levels of your natural cannabinoids. CBD, unlike marijuana, works on the endocannabinoid system without making you high because it does not contain enough tetrahydrocannabinol (THC). That’s the component of marijuana responsible for its psychoactive effects.

 

Even though your body makes endocannabinoids, many aspects of modern life can lead to an endocannabinoid deficiency (more on this later). That’s when hemp-based CBD oil can be especially effective.

 

Your Body’s Locks and Keys

 

Cells throughout your body have receptors. These receptors act like locks. They need certain substances that act like keys to open or close the receptor locks. Depending on the cell’s location in the body and receptor involved, this can open or close different doors to health or disease depending upon whether the substance acting like a receptor key is beneficial or harmful and whether it locks or unlocks the receptor. Substances that bind to receptors to act like keys include drugs, hormones, and neurotransmitters (chemicals released from nerve cells).

 

In 1988, scientists Allyn Howlett and William Devane at the St. Louis University School of Medicine discovered that brains in mammals have receptors that react to cannabis-derived compounds.1 These receptors are known as cannabinoid receptors. They’re the most abundant form of neurotransmitter receptor in the brain. These cannabinoid receptors respond to endocannabinoids. Plant-derived cannabinoids such as CBD from hemp and THC from marijuana also interact with these receptors.

 

CB1 and CB2 were the first two cannabinoid receptors discovered.1 CB1 receptors are primarily located in the brain.1 By contrast, CB2 receptors are located in the gastrointestinal (GI) tract, liver, spleen, endocrine glands, and the reproductive system.1 The immune system and the peripheral nervous system also contain CB2 receptors.1 The peripheral nervous system is the part of the nervous system located outside the brain and spinal cord.

 

The Endocannabinoid System’s Role in Your Health

 

There is a lot more for us to learn about the endocannabinoid system’s role in health. However, thousands of studies have now explored the many ways in which this system benefits us. The table below shows in which health concerns the endocannabinoid system plays a role.

 

  Table 1: The Many Ways the Endocannabinoid System Regulates Health
Gut Health • The endocannabinoid system is involved in regulating visceral pain and irritable bowel syndrome.2,3

• Endocannabinoids also help ensure we don’t get constipated or develop diarrhea.3

• The endocannabinoid system helps regulate intestinal permeability, meaning it can support the health of people with leaky gut.4

• The phytocannabinoid CBD may have a role to play in supporting the health of people with ulcerative colitis.5

 

Brain Function and Mental Health • Endocannabinoids play a role in the gut-brain axis, the communication that occurs between the gut and the brain.6

• The endocannabinoid system is involved in regulating anxiety, posttraumatic stress disorder, depression, bipolar disorder, and schizophrenia.7

 

Pain • CB2 receptors stimulate opioid receptors to cause pain relief in a non-addictive manner.8

• CB2 receptors may be involved in blocking the effect of painful stimuli in inflammatory processes of the nervous system.9

• The endocannabinoid system may be the reason why stress can lead to abdominal pain.3

• The pain-relieving effects of acetaminophen may be because one of its metabolites indirectly activates CB1 receptors.10

• The endocannabinoid system also is involved in the regulation of endometriosis-associated pain.11

Joint Health • In rat studies of animals with osteoarthritis, transdermal or oral CBD improved joint health, reduced joint inflammation and swelling, and improved the ability of the animals to bear their own weight. CBD administered in advance of inducing osteoarthritis in animals blocked the development of joint pain and nerve damage.12,13

• Researchers have found cannabinoid receptors on human articular cartilage from patients with symptomatic osteoarthritis.14

Stress • CBD’s role in promoting a calm mood is related to its effects on the serotonin receptor and the ability to control blood flow in regions of the brain involved in anxiety.15

• A number of clinical studies have shown CBD has a calming effect on people who have to give a public speech.16-19

Sleep • Low-dose CBD can be stimulating and lead to wakefulness. However, higher doses of CBD can encourage restful sleep.20

• CBD may reduce stress and improve the quality and quantity of sleep.21

• CBD may be beneficial in REM sleep behavior disorder (a condition where people kick, move, or act out dreams in their sleep) and to feel less sleepy during the day.22

Women’s Health • The endocannabinoid system plays an important role in fertility.23

• The endocannabinoid system is present within ovaries.24

• CBD may reduce discomfort in women with endometriosis.25

• Menopausal health and breast health may also be regulated by the endocannabinoid system.26,27

Men’s Health • CBD may play a role in prostate health.28,29

 

Urinary Tract Health • Cannabinoid receptors are present in the lower urinary tract and areas involved in urinary tract control.30

• Phytocannabinoids may support the health of the bladder, urethra, and prostate.30

Epilepsy • CBD, administered together with anti-seizure medication, can support the health of people with seizures.31-34
Immunity • The endocannabinoid system can be involved in both enhancing and suppressing immunity.35

• The endocannabinoid system is involved in the body’s response to respiratory syncytial virus (RSV), the primary cause of severe bronchiolitis and pneumonia in children.36-38

• CBD can support a healthy immune response in the liver.39

• All five major cannabinoids—cannabidiol, cannabichromene, cannabigerol, THC, and cannabinol—help control a variety of methicillin-resistant Staphylococcus aureus (MRSA) strains of bacteria.40

 

Inflammation • Cannabinoids play a role in the recruitment of immune cells to the location of intestinal inflammation.41

• Cannabidiol also has been shown to block the production of pro-inflammatory proteins known as cytokines.42

• CBD has reduced markers of inflammation in a number of cell culture and animal studies.43-46

• Cannabinoids ability to support a healthy inflammatory response are not associated with the adverse effects produced by NSAIDs.47

 

ADHD/Autism

 

• Researchers have observed low levels of certain endocannabinoids in children with autism spectrum disorder (ASD).48

• Problems with endocannabinoid function are thought to play a role in the social challenges that occur in kids with ASD.49

• In adults with ADHD, CBD may help reduce hyperactivity, impulsivity, and ability to control behavior. However, more studies are needed in this group of people.50

 

Getting To Know The Endocannabinoids

 

There are two main endocannabinoids produced in the body: anandamide (AEA) and 2-arachidonoylglycerol (2-AG). These activate CB1, CB2, and other receptors in the endocannabinoid system, serving as the “keys” that fit into the receptor “locks” (more on this later). Each of these endocannabinoids play an important role in health. AEA is involved in the perception of pain, emotional health, and energy metabolism (the body’s generation of energy from nutrients).51 It is nicknamed “the bliss molecule” since it’s involved in mood.

 

Like AEA, 2-AG is found throughout the body including the brain, cardiovascular system, and intestines.52,1 2-AG may even be involved in orgasms during sex, indicating that AEA isn’t the only bliss molecule.53

 

Another key player in the endocannabinoid system are enzymes that break down the endocannabinoids. For example, the enzyme fatty acid amide hydrolase—FAAH for short—breaks down AEA.54  Some substances like CBD can increase levels of AEA by blocking FAAH actions.55 Blocking FAAH may help support pain management and neurodegenerative health and relieve occasional anxiety.54

 

Endocannabinoid Deficiency

 

Certain factors can cause what’s known as endocannabinoid deficiency. This happens when the body doesn’t make enough endocannabinoids to maintain optimal health or there are a reduced number of cannabinoid receptors. For example, early life stress leads to changes in AEA and 2-AG tissue levels within the amygdala and hippocampus regions of the brain.56 Stress in early childhood can also reduce the number of CB1 receptors in all brain regions later in life.56 These changes can lead to an inability to cope with stress as time goes on.56

 

Endocannabinoid deficiency can also result due to genetic reasons or because of disease or injury.1 Researchers have proposed that endocannabinoid deficiency may be the cause of migraines, fibromyalagia, and irritable bowel syndrome.1 It may also play a role in autism spectrum disorder.1

 

A Balancing Act

 

The goal is not always to increase endocannabinoid levels. Instead, sometimes lowering endocannabinoid levels is what is needed for optimal health. We must always strive for a balanced endocannabinoid system. For example, lower AEA was associated with the improvement in migraines that occur when patients with these headaches participate in aerobic exercise.57 In addition, weight loss and improved mood after aerobic exercise training are linked to lower plasma AEA in healthy people.58 In addition, high 2-AG levels are linked to excessive hunger in sleep-deprived people.59 

 

Beyond Cannabinoid Receptors

 

Earlier, we discussed the cannabinoid receptors CB1 and CB2. However, endocannabinoids, CBD, and other hemp-derived cannabinoids interact with other receptors, too. Here are some of these other receptors:

 

  • G-protein coupled receptors (GP- CRs: GPR18, GPR55 and GPR119) – GPR18 is expressed primarily in immune cells while GPR55 is expressed in several brain areas as well as in some neurons with larger diameters.60 GPR55 may also be expressed in the immune system as well as in immune-regulating cells located in the brain and spinal cord known as microglia.60 GPR55 can also be activated in the bone.60

 

  • Type 1 vanilloid receptors (TRPV1) – These receptors may be involved in some of the beneficial effects of cannabinoids. For example, scientists have found TRPV1 receptors in neurons that play a role in pain management.61

 

  • Serotonin receptor (5-HT1A) – Scientists have shown that endocannabinoids and plant-derived cannabinoids can affect the serotonin receptor subtype 5-HT1A. Serotonin is known as the “feel-good” neurotransmitter. Optimal levels of this neurotransmitter lead to a sense of well-being and happiness. The mood-boosting effects of CBD are due in part to activation of the 5-HT1A receptor.62
  • Other cannabinoid receptors – Cannabinoids may interact with other receptors. These other receptors may be involved in some of the pain-relieving effects linked to cannabinoids.63,64

The Pain-Killing Endocannabinoid Lookalike

 

There is a substance known as palmitoylethanolamide (PEA). It’s not an endocannabinoid but it works on the endocannabinoid system by helping the body make better use of the endocannabinoid AEA.65 PEA is best known for its role in pain management. PEA is a natural painkiller.65 Your body makes it when it’s in pain. PEA is also found in some foods including egg yolks, peanuts, and soybeans. However, it’s not found in cannabis.

 

There’s now a lot of evidence to indicate PEA reduces neuroinflammation, a process that’s linked to pain.65 It does this in part by blocking mast cells and regulating glial cells in the central nervous system.65 If you have hay fever then you’re all too familiar with what overactivated mast cells can do. They release inflammatory substances such as histamine. Glial cells play a role in the health of your neurons.

 

Researchers reviewed the results of 12 clinical trials to find out whether PEA could reduce pain.65 The researchers concluded that PEA supplementation was better at progressively decreasing pain intensity compared with control. According to these scientists, “These results confirm that PEA might represent an exciting, new therapeutic strategy to manage chronic and neuropathic pain associated with neuroinflammation.”

 

The Remarkable Cannabinoid System

 

Cannabinoids—both the endocannabinoids made in your body and hemp-based cannabinoids like CBD—play a role in virtually every area of health. Well-being and happiness, pain management, a healthy digestive system, a good night’s rest, a strong immune system, reproductive health, and healthy joints are all dependent upon this system. Taking steps to keep your endocannabinoid system healthy is therefore critical to optimal health.

 

The statements mentioned in this content have not been evaluated by the FDA, and are not intended to prevent, diagnosis, or treat any disease. Always work with your personal healthcare provider.

 

References:

 

  1. Smith SC, Wagner MS. Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinology Letters. 2014;35(3):198-201.
  2. Sakin YS, Dogrul A, Ilkaya F, et al. The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceralpain models in Rodents. Neurogastroenterol Motil. 2015 Jul;27(7):936-44.
  3. Sharkey KA, Wiley JW. The Role of theEndocannabinoid System in the Brain-Gut  Gastroenterology. 2016 Aug;151(2):252-66.
  4. Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids–at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2016 Mar;12(3):133-43.
  5. Irving PM, Iqbal T, Nwokolo C, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018 Mar 19;24(4):714-24.
  6. DiPatrizio NV. Endocannabinoids in the Gut. Cannabis Cannabinoid Res. 2016 Feb;1(1):67-77.
  7. Rubino T, Zamberletti E, Parolaro D. Endocannabinoids and Mental Disorders. Handb Exp Pharmacol.2015;231:261-83.
  8. Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3093-8.
  9. Manzanares J, Julian MD, Carrascosa A. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. Curr Neuropharmacol. 2006 Jul; 4(3): 239-57.
  10. Klinger-Gratz PP, Ralvenius WT, Neumann E, et al. Acetaminophen Relieves InflammatoryPain through CB1 Cannabinoid Receptors in the Rostral Ventromedial Medulla. J Neurosci. 2018 Jan 10;38(2):322-34.
  11. Sanchez AM, Cioffi R, Viganò P, et al. Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis. Reprod Sci. 2016 Aug;23(8):1071-9.
  12. Philpott HT, O’Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. 2017 Dec;158(12):2442-51.
  13. Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity ofcannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):294-9.
  14. Dunn SL, Wilkinson JM, Crawford A, et al. Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies. CannabisCannabinoid Res. 2016 Jan 1;1(1):3-15.
  15. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011 Jan;25(1):121-30.
  16. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016 Fall;20(4):16-005.
  17. Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol. Curr Neuropharmacol. 2017;15(2):291-9.
  18. Linares IM, Zuardi-AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019 Jan-Feb;41(1):9-14.
  19. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiolreduces the anxiety induced by simulated public speaking in treatment-naïve socialphobia patients. Neuropsychopharmacology. 2011 May;36(6):1219-26.
  20. Carlini EA, Cunha JM. Hypnoticand antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981 Aug-Sep;21(S1):417S-27S.
  21. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016 Fall;20(4):16-005.
  22. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23.
  23. Walker OS, Holloway AC, Raha S. The role of the endocannabinoid system in female reproductive tissues. J Ovarian Res. 2019:12:3.
  24. El-Talatini MR, Taylor AH, Elson JC, et al. Localisationand function of the endocannabinoid system in the human ovary. PLoS One. 2009;4(2):e4579.
  25. Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: a national online survey. BMC Complement Altern Med. 2019 Jan;19:17.
  26. Abdulnour J, Yasari S, Rabasa-Lhoret R, et al. Circulatingendocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity (Silver Spring). 2014 Jan;22(1):211-6.
  27. Kisková T, Mungenast F, Suváková M, et al. Future Aspects for Cannabinoids in Breast Cancer Therapy. Int J Mol Sci. 2019 Apr;20(7):1673.
  28. Fraguas-Sánchez AI,Fernández-Carballido A, Torres-Suárez AI. Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate  Expert Opin Investig Drugs. 2016 Nov;25(11):1311-23.
  29. Orellana-Serradell O, Poblete CE, Sanchez C, et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep. 2015 Apr;33(4):1599-608.
  30. Ruggieri MR Sr. Cannabinoids: potential targets for bladder dysfunction. Handb Exp Pharmacol. 2011;(202):425-51.
  31. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-20.
  32. Devinsky O, Patel AD, Cross JH, et al. Effectof Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-97.
  33. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in Patients with Seizures Associated with Lennox-Gastaut Syndrome (GWPCARE4): a randomized double-blind,placebo-controlled phase 3 trial. 2018 Mar 17;391(10125):1085-96.
  34. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. 1980;21(3):175-85.
  35. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol. 1998 Mar 15;83(1-2):102-15.
  36. Kaplan BLF. Endocannabinoidengagement of CB2 regulates RSV-induced immunity. 2018 Jan 1;9(1):494-5.
  37. Tahamtan A, Samieipoor Y, Nayeri FS, et al. Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. 2018 Jan 1;9(1):217-30.
  38. Tahamtan A, Tavakoli-Yaraki M, Shadab A, et al. The Role of Cannabinoid Receptor 1 in the Immunopathology of Respiratory Syncytial Virus. Viral Immunol. 2018 May;31(4):292-8.
  39. Lowe HI, Toyang NJ, McLaughlin W. Potential ofCannabidiol for the Treatment of Viral  Pharmacognosy Res. 2017 Jan-Mar;9(1):116-8.
  40. Appendino G, Gibbons S, Giana A, et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod. 2008 Aug;71(8):1427-30.
  41. Alhouayek M, Lambert DM, Delzenne NM, et al. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 2011 Aug;25(8):2711-21.
  42. Schicho R, Bashashati M, Bawa M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis.2011 Aug;17(8):1651-64.
  43. Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl).2009 Nov;87(11):1111-21.
  44. De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One. 2011;6(12):e28159.
  45. Petrosino S,Verde R, Vaia M, et al. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. J Pharmacol Exp Ther. 2018 Jun;365(3):652-63.
  46. Parker J, Atez F, Rossetti RG, et al. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol Int. 2008 May;28(7):631-5.
  47. Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016 Nov;30(11):3682-9.
  48. Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018 Mar 12;9:18.
  49. Wei D, Lee D, Cox CD, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci USA. 2015 Nov 10;112(45):14084-9.
  50. Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017 Aug;27(8):795-808.
  51. Oliveira AB, Ribeiro RT, Mello MT, et al. AnandamideIs Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial. Cannabis Cannabinoid Res. 2019 Dec 9;4(4):275-84.
  52. Science Direct. 2-Arachidonoylglycerol. Comprehensive Natural Products II. 2010. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/2-arachidonoylglycerol. Accessed January 20, 2020.
  53. Fuss J, Bindila L, Wiedemann K, et al. Masturbation toOrgasm Stimulates the Release of the Endocannabinoid 2-Arachidonoylglycerol in Humans. J Sex Med. 2017 Nov;14(11):1372-9.
  54. Maccarrone M, Finazzi-Agrò A. Anandamide hydrolase: a guardian angel of human reproduction? Cell. 2004 Jul. 25(7):353-7.
  55. Fogaça MV, Campos AC, Coelho LD, et al. The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling. 2018 Jun;135:22-33.
  56. Goldstein Ferber S, Trezza V, Weller A. Early life stress and development of the endocannabinoid system: A bidirectional process in programming future coping. Dev Psychobiol. 2019 Dec 18. [Epub ahead of print.]
  57. Oliveira AB, Ribeiro RT, Mello MT, et al. AnandamideIs Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial. Cannabis Cannabinoid Res. 2019 Dec 9;4(4):275-84.
  58. Belitardo de Oliveira A, de Mello MT, Tufik S, Peres MFP. Weight loss and improved mood afteraerobic exercise training are linked to lower plasma anandamide in healthy people. Physiol Behav. 2019 Mar 15;201:191-7.
  59. Hanlon EC, Tasali E, Leproult R, et al. Sleep Restriction Enhances the Daily Rhythm of Circulating Levels of Endocannabinoid 2-Arachidonoylglycerol. 2016 Mar 1;39(3):653-64.
  60. Miller RJ, Miller RE. Is cannabis an effective treatment for jointpain? Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):59-67.
  61. O’Hearn S, Diaz P, Wan BA, et al. Modulating theendocannabinoid pathway as treatment for peripheral neuropathic pain: a selected review of preclinical studies. Ann Palliat Med. 2017 Dec;6(Suppl 2):S209-14.
  62. Sartim AG, Guimarães FS, Joca SR. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res. 2016 Apr 15;303:218-27.
  63. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001 Jul;60(1):155-63.
  64. Hájos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. 2001;106(1):1-4.
  65. Paladini A, Fusco M, Cenacchi T, et al. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Pain Physician. 2016;19:11-24.

 

 

Chapter 2

CBD’s Mechanisms in the Body: How This Amazing Cannabinoid Keeps You Healthy

 

Cannabidiol (CBD) from hemp oil has taken center stage recently as a way to address many areas of health including supporting a healthy pain response in the joints and other areas of the body, dealing with occasional sleep problems and everyday stress, and supporting a healthy attention span, focus, and concentration, to name just a few of its benefits. (I summarized its health benefits in Table 1 of Chapter 1, and I’ll be talking more about those benefits as this book unfolds.) In June 2018, CBD ended up even more in the spotlight when the US Food and Drug Administration (FDA) approved the first CBD-based drug, Epidiolex®, for treatment of rare, severe epilepsy.

 

Is CBD the Answer to the Opioid Addiction Crisis?

 

Overuse of opioid drugs, which are highly addictive and lead to fatal overdoses, has hit epidemic proportions. Every day, 128 people in the United States die from an opioid overdose.1

It’s estimated that 21% to 29% of people using opioids for chronic pain misuse these drugs.2

Not only are opioids potentially dangerous, but taking opioids can actually backfire. Sometimes a patient taking opioids for the treatment of pain could instead make the pain worse since they react even more to certain painful stimuli.3

 

This crisis has its origins in 1937, when German scientists at the IG Farben company first synthesized the opioid medication methadone to use for surgery-related pain. They claimed it was less addictive than morphine or heroin. However, this claim was clearly false. Methadone is longer-acting than morphine or heroin.4 It’s more addictive than these substances and causes withdrawal symptoms that last longer.4

 

Pharmaceutical companies began releasing new opioid painkillers including Vicodin® (a combination of Hydrocodone Bitartrate and acetaminophen) in 1984, OxyContin® in 1995, and Percocet® (Oxycodone plus acetaminophen) in 1999.5 This led to an onslaught of opioid over-prescribing. After all, the pharmaceutical industry assured physicians that these medications were not addictive.1

 

In 2007 came a turnaround point. Purdue Frederick Company Inc., an affiliate of Purdue Pharma, along with three of the company’s executives admitted to misbranding OxyContin®. The company had made false statements about the drug, claiming it was less addictive than other opioids and that people taking it were less likely to abuse it. Purdue Frederick pleaded guilty to criminal charges and paid $634 million in fines.6

 

Clearly, we need another alternative to support a healthy pain response. And that alternative may very well be CBD, which does not produce a high and isn’t addictive. Later in this book, I’ll discuss CBD’s ability to support comfortable knee and hip joints, as well as promote a healthy pain response in the neck, back, and more. For now, let’s take a look at the way in which CBD can benefit so many areas of health.

 

How CBD Works

 

CBD has shown a lot of promise both in doctor’s offices and in studies.  But how does this hemp-derived cannabinoid work?

 

As a reminder, in Chapter 1, I covered CBD’s effects on CB1 and CB2 receptors and how CBD acts like a key that fits into those receptor locks. These receptors are part of what’s known as the endocannabinoid system, which plays a role in keeping us healthy, both physically and mentally. I also discussed the other receptors that CBD acts upon and explained that two main endocannabinoids produced in the body—anandamide (AEA) and 2-arachidonoylglycerol (2-AG)—activate these same receptors. A lot of what we know about CBD comes from what researchers have observed about the effects of AEA and 2-AG on the body.

 

In Chapter 1, I also delved briefly into the effects of an enzyme known as FAAH. This enzyme breaks down the endocannabinoid AEA. In doing so, it generally weakens AEA’s beneficial effects. AEA is sometimes called the “bliss molecule” since it plays an important part in maintaining a happy mood and staying optimistic. CBD can increase levels of AEA by blocking FAAH.7 Blocking FAAH may help support pain management and neurodegenerative health, maintain healthy levels of beta-amyloid proteins, and relieve occasional stress and frustration.8-12 When people take opioids, they start to become tolerant to the drugs’ effects, so they have to take higher and higher doses for these medications to remain effective. Based on results of animal research, blocking FAAH may also stop this tolerance to opioids.13  

 

Meet MAGL

 

In this chapter, I am going to introduce another enzyme involved in the endocannabinoid system. It’s called monoacylglycerol lipase—MAGL for short. While FAAH breaks down the endocannabinoid AEA, MAGL breaks down AEA’s endocannabinoid sibling 2-AG.14 In animal studies, blocking MAGL maintains gastric health when taking non-steroidal anti-inflammatory drugs (NSAIDs).14 These type of drugs—such as aspirin and ibuprofen—are extremely damaging to gastric health and can cause ulcers. Patients with ulcerative colitis also have elevated MAGL levels, suggesting that in these people the endocannabinoid 2-AG is being broken down faster.15

 

Blocking MAGL also can strengthen the intestinal wall, possibly reducing leaky gut.14 This is a condition where weakened intestinal walls leads to the escape of food particles and inflammatory substances into the circulation. This can cause problems throughout the body. Leaky gut is linked to food intolerances, brain health, and much more. In fact, in my patients, I have noticed that resolving leaky gut leads to dramatic improvements in overall health.

 

CBD reduces MAGL’s ability to break down the endocannabinoid 2-AG.16  CBD’s ability to block MAGL’s actions may be part of the reason it can produce feelings of calm during occasional stress, promote a healthy gastrointestinal tract, and reduce cravings in people with addictions.14,16,17 By blocking the enzymes FAAH and MAGL, CBD may protect the GI tract from the negative effects of NSAIDs since the GI damage caused by these medications is linked to FAAH and MAGL activity.18,19

Beyond CBD’s Healthful Properties

 

CBD is the most talked about cannabinoid in hemp because it’s found in high levels. But hemp also contains other phytocannabinoids that are beneficial to health. These are found at much lower levels than CBD, but work together with CBD to provide synergistic benefits. And these other phytocannabinoids even have healthful properties on their own. One of these phytocannabinoids is cannabigerol (CBG). CBG is antibacterial and supports a healthy inflammatory response.20,21 What’s more, it can promote well-being and happiness, thanks to its ability to increase the “bliss molecule” anandamide.22

 

CBG also promotes a healthy pain response, supports healthy cells in the colon and other areas of the body, and is neuroprotective.22-25 In fact, CBG and CBD each have different neuroprotective effects, indicating they can work together to support brain and nervous system health in people with neurodegenerative concerns.25 In addition, Cannabis with high levels of CBD and CBG inhibits the activity of the enzyme aldose reductase in human cell culture studies.26 Blocking aldose reductase is involved in diabetic health.

 

Cannabinol (CBN) is another phytocannabinoid in hemp. In animal research, CBN teamed up with CBD to support comfortable muscles and temporomandibular health.27

 

The “Hemptourage Effect”

 

Two decades ago, Doctors Mechoulam and Ben-Shabat proposed a concept known as the entourage effect.28,29 Originally, it referred to the ability of certain endocannabinoid system components to boost the beneficial effects of the two most important actors in this system: anandamide and 2-arachidonylglycerol.28

 

Today, the entourage effect is commonly used to refer to an interesting phenomenon: the ability of CBD to work together with its other minor components to produce even greater health benefits. The term “hemptourage effect” is now used to describe the potential synergistic interactions that take place between the CBD in hemp oil and hemp’s other constituents.

 

Terrific Terpenes

 

Substances in hemp that work together with CBD are called terpenes, which contain beneficial compounds known as terpenoids, the largest group of plant chemicals. Some of these terpenes are also found in cannabis and are responsible for its aroma. The table below shows some of the ways these terpenes can promote health.

 

Some Terpenes Found in Hemp and How They Benefit Health22,29
D-Limonene • Also found in citrus fruits, d-limonene is relaxing. In rodent studies, it has increased brain levels of two hormones related to mood and happiness: serotonin and dopamine (DA).

• Inhaling citrus fragrance improved mood in depressed human subjects. Nine of the 12 subjects were able to stop taking antidepressant medications.

• D-limonene also supported healthy immunity.

Myrcene • Supports a healthy inflammatory response and a healthy liver after exposure to toxins.

• In rodent studies, acts like an analgesic and relaxes muscles.

• Promotes relaxation and sleep.

 

D-Linalool  

• Also found in lavender, linalool is calming.

 

• Acted as an anti-convulsant in rodents and inhibited seizures.

 

• Compared with a placebo, inhaling lavender decreased the use of morphine opioids in morbidly obese people who underwent gastric banding surgery.

 

 

α-Pinene • α-Pinene is the most common terpenoid in nature. In addition to hemp, it’s found in conifer trees and other plant essential oils, where it acts like a natural insect repellant.

• It supports a healthy inflammatory response.

• A human study found it supported lung health by clearing the airways.

• It supports cognitive function. This could mean it acts synergistically with CBD in counteracting the short-term memory problems caused by THC intoxication after marijuana use.

• In a mouse study, essential oils that included pinene and limonene enhanced absorption of estrogen through the skin.

Nerolidol • Also found at low levels in citrus fruit peels, nerolidol is calming.

• A rodent study found it supports colon health.

• It may also be able to stop fungal growth.

• May weaken protozoan parasites such as malaria and leishmania.

Caryophyllene (Humulene) • Also found in lemon balm (Melissa officinalis) and eucalyptus.

• Serves as a natural insecticide and antifungal in plants.

• May block fungal growth.  An 8% concentration eradicated a fungal infection in 15 days.

• In cell culture research, it stopped blood platelets from sticking together.

• Reduced paw swelling in rodents given an inflammatory substance.

Phytol • Present in hemp extracts through the breakdown of chlorophyll and tocopherol.

• Leads to relaxation thanks to its ability to raise levels of the calming neurotransmitter GABA. It blocks an enzyme responsible for breaking down GABA.

beta-Amyrin • Supports a healthy inflammatory response and the body’s response to unwanted microorganisms and fungus.

 

 

Teaming Up with Terpenes

 

Many terpenes found in hemp may work together with CBD and other phytocannabinoids in hemp. In fact, many terpenes have complimentary actions to CBD. Take a look at the table below to get an idea how these terpenes work together with other components of hemp oil. Since this is such a large topic, I’ll devote a chapter to terpenes later on in the book.

 

How Terpenes Work Together with Other Hemp Components22
Limonene + Linalool + Pinene + CBD  

• CBD reduces the increased sebum production linked to acne.

 

• Limonene was more effective at suppressing Propionibacterium acnes, an acne-related pathogen, compared with triclosan. Linalool and limonene are known to reduce markers of P. acnes-related inflammation.

 

• Pinene suppresses  P. acnes and Staph spp.

• CBD supports cognitive function in people exposed to THC from cannabis, which is known to affect memory.  In cell culture, CBD also reduces formation of beta-amyloid proteins. Low levels of beta-amyloid is linked to a healthy memory during aging.  Limonene, pinene, and linalool likely work with CBD to support cognitive health through their ability to improve mood.

• Pinene also improves mental focus, thus acting synergistically to CBD’s ability to support a sharp memory.

Pinene + CBD + CBG • Pure CBD and CBG blocked methicillin-resistant Staphylococcus aureus

(MRSA) in a structure-activity study. This type of study looks at the link between a substance’s chemical structure and its actual biological activity against a microorganism.

 

• High-pinene essential oils were also effective against MRSA and other antibiotic-resistant bacteria.

Limonene + linalool + CBD • CBD is calming and reduces everyday stress.  Researchers have proposed that using limonene and linalool with CBD could add to CBD’s relaxing effects since both of these terpenes are also very calming.

 

Hemp’s Powerful Health Benefits

 

Now that I’ve discussed the mechanisms involved in the beneficial effects of CBD and other components of hemp, in the chapters that follow I’ll go into detail about the specific ways CBD from hemp oil can make you feel happier and healthier.

 

References:

 

  1. National Institute on Drug Abuse. Opioid Overdose Crisis. https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis#one Accessed April 1, 2020.
  2. Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015 Apr;156(4):569-76.
  3. Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011 Mar-Apr;14(2):145-61.
  4. Nemat Shahi M, Asadi A, Behnam Talab E, et al. The Impact of Saffron on Symptoms of Withdrawal Syndrome in Patients Undergoing Maintenance Treatment for OpioidAddiction in Sabzevar Parish in 2017. Adv Med. 2017;2017:1079132.
  5. Foundation for a Drug-Free World. http://www.drugfreeworld.org/drugfacts/painkillers/a-short-history.html Accessed April 1, 2020.
  6. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009 Feb;99(2):221-7.
  7. Fogaça MV, Campos AC, Coelho LD, et al. The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling. Neuropharmacology. 2018 Jun;135:22-33.
  8. Crivelaro do Nascimento G, Ferrari DP, Guimaraes FS, et al. Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson’s disease. Neuropharmacology. 2020 Feb;163:107808.
  9. Greco R, Demartini C, Zanaboni AM, et al. FAAHinhibition as a preventive treatment for migraine: A pre-clinical study. Neurobiol Dis. 2020 Feb;134:104624.
  10. Sun J, Zhou YQ, Chen SP, et al. The endocannabinoid system: Novel targets for treating cancer induced bonepain. Biomed Pharmacother. 2019 Dec;120:109504.
  11. Ren SY, Wang ZZ, Zhang Y, Chen NH. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing onFAAH/MAGL inhibitors. Acta Pharmacol Sin. 2020 Mar 18. [Epub ahead of print.]
  12. Danandeh A, Vozella V, Lim J, et al. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-termanxiety. Psychopharmacology (Berl). 2018 Nov;235(11):3211-21.
  13. Fotio Y, Palese F, Guaman Tipan P, et al. Inhibition of fatty acid amide hydrolase in the CNS prevents and reverses morphine tolerance in male and female mice. Br J Pharmacol. 2020 Feb 19. [Epub ahead of print.]
  14. Gyires K, Zádori ZS. Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol. 2016;14(8):935-51.
  15. Marquéz L, Suárez J, Iglesias M, et al. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One. 2009 Sep 4;4(9):e6893.
  16. Papagianni EP, Stevenson CW. Cannabinoid Regulation of Fear and Anxiety: an Update.Curr Psychiatry Rep. 2019;21:
  17. Galaj E, Xi ZX. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs. 2019 Oct;33(10):1001-30.
  18. Deplano A, Karlsson J, Svensson M, et al. Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen. J Enzyme Inhib Med Chem. 2020 Dec;35(1):815-23.
  19. Crowe MS, Kinsey SG. MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice. Eur J Pharmacol. 2017 Jul 15;807:198-204.
  20. Appendino G, Gibbons S, Giana A, et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod. 2008 Aug;71(8):1427-30.
  21. Mammana S, Cavalli E, Gugliandolo A, et al. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol. Medicina (Kaunas). 2019 Nov 18;55(11). pii: E747.
  22. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344-64.
  23. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000 Dec;60(6):1303-14.
  24. Borrelli F, Pagano E, Romano B, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonistcannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014 Dec;35(12):2787-97.
  25. di Giacomo V, Chiavaroli A, Orlando G, et al. Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus. Antioxidants (Basel). 2020 Jan 13;9(1). pii: E71.
  26. Smeriglio A, Giofrè SV, Galati EM, et al. Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. Fitoterapia. 2018 Jun;127:101-8.
  27. Wong H, Cairns BE. Cannabidiol,cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019 Aug;104:33-9.
  28. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol.1998 Jul 17;353(1):23-31.
  29. Komori T, Fujiwara R, Tanida M, et al. Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation.1995 May-Jun;2(3):174-80.

 

 

Chapter 3

CBD and Its Role in Calming Stress

 

The statements mentioned in this content have not been evaluated by the FDA, and are not intended to prevent, diagnosis, or treat any disease. Always work with your personal healthcare provider.

 

Fear, stress, and anxiety are normal responses triggered when the body perceives threats to survival. However, in modern times, we encounter situations such as deadlines at work, unemployment, financial challenges, caring for our elderly relatives, and many other situations that cause our body to get stuck in stress mode. This leads to excessive and ongoing fear, stress, and anxiety. A number of mental disorders are also associated with excessive fear and anxiety, including  generalized anxiety disorder (GAD), panic disorder (PD), post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and obsessive-compulsive disorder (OCD).

CBD can soothe mild stress and anxiety by virtue of its effects on the central nervous system.1,2

CBD interacts with several receptors that regulate fear and anxiety-related behaviors such as the cannabinoid receptor CB1, the serotonin 5-HT1A receptor, and the transient receptor potential (TRP) vanilloid type 1 (TRPV1) receptor.3 I discussed these receptors in detail in chapter 1. Remember that CBD works through the endocannabinoid system. And the endocannabinoid system plays an important role in reducing stress and anxiety.

Your Body’s Own Stress-Reduction Mechanism

The endocannabinoid system regulates emotional behavior. It determines how you respond to unpleasant events and leads to an appropriate response to stress.4-6 As I talked about in previous chapters, endocannabinoids that are part of the endocannabinoid system activate CB1 receptors. These endocannabinoids act like locks that fit into the receptor “key.” Activation of CB1 receptors regulates anxiety and fear.6 In animal research, CB1 receptor activation led to an improved response to bad memories.7

When you’re under stress, your body is tasked with sending you back into your non-stress state of peaceful balance. In order to accomplish this, it performs what’s called a negative feedback loop. The loop begins when stress activates the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). This leads to a stress response or stress cascade, as it’s sometimes called. This stress cascade helps the body make the necessary changes required to cope with stress. When the body is knocked out of balance by a stressor it triggers the release of corticotropin-releasing hormone (CRH) from the brain region known as the hypothalamus. This in turn leads to the release of adrenocortiotropin hormone (ACTH) into the circulation. This is a signal for the adrenal cortex to release glucocorticoids into the blood. In an effort to restore your body back into the pre-stress state, the glucocorticoids stop the release of CRH, shutting down the stress response.8

The activation of CB1 receptors also play a critical role in this negative feedback loop that occurs as your body deals with stress. CRH release can lead to anxiety. CRH increases the production of the enzyme fatty acid amide hydrolase (FAAH), which reduces the endocannabinoid anandamide (AEA) within the amygdala of the brain. By activating the CB1 receptor, CRH release is cut off and AEA levels increase, which can have a calming effect.9 On the other hand, chronic, unpredictable stress can throw off the endocannabinoid system in the hippocampus and amygdala of the brain, leading to anxiety.10

CBD works through the endocannabinoid system to soothe stressful feelings.11 Although CBD doesn’t act directly on the CB1 receptor, it can act indirectly.11 It also blocks the actions of FAAH and in doing so increases levels of AEA.11 It may counteract the FAAH-raising effects of CRH.11 CBD can also work through the serotonin receptor.12 Serotonin is a “feel-good” hormone that contributes to feelings of calm and relaxation.

CBD can also modify blood flow in brain areas that are involved in anxiety, such as the amygdala, hippocampus, hypothalamus, and cingulate cortex.13 This is another way in which CBD can produce feelings of calm and relaxation.

CBD and the Stress of Public Speaking

To test whether CBD can relax people who are under stress, scientists undertook several studies of CBD’s effect on people giving public speeches. In one of those studies, researchers caused anxiety in a group of 57 healthy male subjects by having them perform a simulated public speaking test.14 In this double-blind study, the participants were given different doses of CBD (150 mg, 300 mg, 600 mg) or a placebo. CBD (300 mg) significantly reduced anxiety during the speech.

In an earlier study, researchers compared the effects of the anti-anxiety drugs ipsapirone (5 mg) or diazepam (10 mg) with CBD (300 mg) or placebo in 40 healthy volunteers during a simulated public speaking test.15 Compared to the placebo, CBD or ipsapirone were each effective at reducing the anxiety caused by public speaking.

CBD produced the same effects in people with generalized social anxiety disorder (SAD).16 Because a pronounced fear of public speaking is one hallmark of this disorder, researchers had 24 patients with SAD and 12 healthy controls perform a public speaking test.16 In this double-blind, randomized study, 12 of the SAD subjects took 600 mg of CBD 1½ hours before public speaking, while 12 SAD patients received a placebo. The healthy controls didn’t receive any treatment.

The study authors used three methods of determining anxiety levels in the participants. The scientists looked at ratings on the Visual Analogue Mood Scale (VAMS), which allows study subjects to rate their level of anxiety, cognitive impairment, and sedation,  and the Negative Self-Statement Scale (SSPS-N), which is based upon theories that social anxiety is the result of thinking poorly of yourself and believing others also think poorly of you. The researchers also measured blood pressure, heart rate, skin conductance, and physical reactions to stress at six different points during the public speaking test. Compared with the placebo group, SAD patients taking the CBD experienced significantly less anxiety, cognitive impairment, and emotional discomfort during their speech. The CBD-group also was more relaxed when they were anticipating giving the speech. The SAD patients taking the placebo experienced increases on the Negative Self-Statement Scale. Patients in the CBD group experienced almost no increase in negative self-statements. The responses of the SAD patients given CBD were similar to healthy controls, meaning the CBD led to a more normal stress response in regards to public speaking.

 

CBD and Blood Pressure Spikes Caused by Stress

Long-term stress is associated with the development of cardiovascular disease.17 Social isolation, depression, not having enough money, stressful family life, and problems at work are linked to both an increased risk of cardiovascular disease and worsening of already existing cardiovascular conditions.18  Evidence from animal studies and some recent interesting human studies suggest that CBD may regulate the body’s cardiovascular response to stress. Restraining rats is a way that researchers cause stress in the animals. In one study, CBD injections reduced the cardiovascular response to restraint stress and the typical stressed out behavior of the animals when restrained.19

Blood pressure rises when a person is under stress. Two human studies have found that CBD may support healthy blood pressure when we’re feeling anxious about a situation or under physical stress. In one of the randomized, placebo-controlled, double-blind studies, researchers gave 26 healthy males 600 mg of oral CBD or a placebo for a week.20 The men participated in isometric exercise and their blood pressure was measured both during rest and during exercise. In response to stress, participants in the CBD group had lower systolic blood pressure both after the initial dose and after repeated seven days of  use. After a week on CBD, the men’s carotid artery widened and the arteries became more flexible. According to the researchers, “CBD reduces BP at rest after a single dose but the effect is lost after seven days of treatment (tolerance); however, BP reduction during stress persists.”

In the other randomized, placebo-controlled, crossover study, nine healthy male subjects were given 600 mg of CBD or a placebo.18 A crossover study is where scientists place the subjects on one protocol (in this case CBD supplementation) for a specific time and then switch the subjects to the placebo for another period of time. The researchers caused stress in the subjects by exposing them to cold and exercise and giving them a test designed to produce mental stress. Diastolic and systolic blood pressure were significantly lower immediately following the stress test in men who had taken CBD. After exposure to cold, men taking the CBD experienced a significant drop in systolic blood pressure and mean arterial pressure. The researchers also found that diastolic blood pressure was significantly less in the men given CBD during cold stress. During exercise stress, CBD lowered systolic blood pressure and mean arterial pressure.

Researchers believe CBD’s ability to lower blood pressure during stress may be an added benefit of its calming properties.18 By relaxing the mind, it may relax the body and the cardiovascular system, too.

 

 

More Restful Sleep

 

Stress can lead to insomnia and a lack of restorative sleep. CBD’s calming effect can help promote better sleep even during stressful times. CBD may hold promise for REM sleep behavior disorder and excessive daytime sleepiness.21 In patients with post-traumatic stress disorder (PTSD), CBD combined with routine psychiatric care has improved the quality of sleep and reduced nightmares.22

 

In a case study, researchers investigated the effects of CBD on a ten-year-old girl with PTSD due to sexual abuse and who had little parental supervision when the girl was under the age of five.23 The girl had tried pharmaceutical medications, but they only provided partial relief and any benefits were only temporary and accompanied by major side effects. On the other hand, CBD oil led to a prolonged decline in anxiety and steadily improved quality and quantity of sleep. The study authors concluded, “This case study provides clinical data that support the use of cannabidiol oil as a safe treatment for reducing anxiety and improving sleep in a young girl with posttraumatic stress disorder.”

 

Researchers conducted a larger human study of 72 patients whose primary concern was either anxiety or poor sleep.24 The subjects were given CBD along with their usual treatment at a large psychiatric outpatient clinic. CBD supplementation was associated with a significant decline in anxiety in 57 of the patients (79.2%) during the first month of use and the participants continued to feel this increased calmness throughout the study. Sleep improved in 48 of the patients (66.7%) in the first month of CBD supplementation, but these results fluctuated over time, indicating mild improvement. CBD was well tolerated although three of the participants experienced fatigue. The doses used in this study (25 mg/day to 175 mg/day) were much lower compared with other clinical studies that used 300 mg/day to 600 mg/day, which may explain why even though CBD caused a noteworthy decline in anxiety it only resulted in a modest improvement in sleep.

 

Evidence from rodent studies mirror CBD’s beneficial effects in humans. One group of researchers triggered PTSD-like anxiety in rats by having them navigate a maze.25 CBD blocked the suppression in rapid eye movement (REM) sleep caused by anxiety. Getting enough rapid eye movement sleep, the stage in which most of our dreams occur, is essential to feeling refreshed and energized. It’s also important for learning, memory, and happiness.

 

Hemp Oil: Teaming Up with Terpenes

 

Supplementing with hemp oil can provide advantages over CBD alone. As I mentioned in previous chapters, hemp oil contains beneficial compounds known as terpenes, which have their own stress-reducing effects. For example, the terpene d-limonene soothes anxious thoughts by increasing levels of serotonin and dopamine,26 both hormones linked to mood and happiness. Another terpene found in hemp, d-linalool, also promotes relaxation, likely by influencing glutamate and GABA neurotransmitter pathways involved in stress management.27  In mice, d-linalool prevented conflict among the animals.28 Many essential oils known for their stress-relieving properties, such as lavender, contain d-linalool. It’s thought to be the main active component in lavender responsible for the anti-anxiety effects of lavender oil.

 

A third relaxing terpene in hemp is myrcene. Myrcene calms the mind and promotes sleep.27  Nerolidol and phytol are terpenes that, like their other hemp-derived cousins, promote relaxation.27 Phytol is also found in green tea, and its presence there could explain why green tea is so relaxing even though it contains caffeine.27 Phytol raises levels of the calming neurotransmitter GABA and blocks an enzyme responsible for breaking down GABA.27 In mice, nerolidol increases the animals’ interest in exploring brightly lit open areas, an indication of reduced anxiety.29

 

Side Benefits of Reducing Stress

 

By reducing stress, CBD can indirectly enhance a couple other areas of health. First, by promoting feelings of calm under pressure, it can support healthy immunity. Psychological stress is known to reduce immune function.30-33 I will discuss CBD’s potential role in immune support later in this book. Second, by lowering stress, CBD may also support a healthy inflammatory response. Stress is well known to increase inflammation.34 I’ll talk about this aspect of CBD more in future chapters.

 

References:

 

  1. Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78.
  2. Schier AR, Ribeiro NP, Silva AC, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10.
  3. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics.2015 Oct;12(4):825-36.
  4. Riebe CJ, Pamplona FA, Kamprath K, Wotjak CT. Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience. 2012 Mar 1;204:159-85.
  5. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012 Oct 4;76(1):70-81.
  6. Ruehle S, Rey AA, Remmers F, Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol. 2012 Jan;26(1):23-39.
  7. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002 Aug 1;418(6897):530-4.
  8. Miller DB, O’Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism. 2002 Jun;51(6 Suppl 1):5-10.
  9. Gray JM, Vecchiarelli HA, Morena M, et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci. 2015 Mar 4;35(9):3879-92.
  10. Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 2005 Mar;30(3):508-15.
  11. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015 Feb;172(3):737-53.
  12. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005 Aug;30(8):1037-43.
  13. Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol. Curr Neuropharmacol.2017;15(2):291-9.
  14. Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019 Jan-Feb;41(1):9-14.
  15. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993 Jan;7(1 Suppl):82-8
  16. Bergamaschi M, Queiroz R, Chagas M,et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients.  2011;36:1219-26.
  17. Figueredo VM. The time has come for physicians to take notice: the impact of psychosocial stressors on the heart. Am J Med. 2009 Aug;122(8):704-12.
  18. Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017 Jun 15;2(12). pii: 93760.
  19. https://www.ncbi.nlm.nih.gov/pubmed/19133999Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009 Jan;156(1):181-8.
  20. Sultan SR, O’Sullivan SE, England TJ. The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial. Br J Clin Pharmacol. 2020 Mar 3. [Epub ahead of print.]
  21. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23.
  22. Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J Altern Complement Med. 2019 Apr;25(4):392-7.
  23. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016 Fall;20(4):16-005.
  24. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041.
  25. Hsiao YT, Yi PL, Li CL, Chang FC. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012 Jan;62(1):373-84.
  26. Agatonovic-Kustrin S, Kustrin E, Gegechkori V, Morton DW. Anxiolytic Terpenoids and Aromatherapy for Anxiety and Depression. Adv Exp Med Biol.2020;1260:283-96.
  27. Russo EB. Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. Br J Pharmacol. 2011 Aug;163(7):1344-64.
  28. Umezu T, Nagano K, Ito H, et al. Anticonflict Effects of Lavender Oil and Identification of Its Active Constituents. Pharmacol Biochem Behav.2006 Dec;85(4):713-21.
  29. Goel RK, Kaur D, Pahwa P. Assessment of Anxiolytic Effect of Nerolidol in Mice. Indian J Pharmacol. Jul-Aug 2016;48(4):450-2.
  30. Moirasgenti M, Doulougeri K, Panagopoulou E, Theodoridis T. Psychological stress reduces the immunological benefits of breast milk. Stress Health. 2019;35(5):681-5.
  31. Crucian BE, Choukèr A, Simpson RJ, et al. Immune system dysregulation during spaceflight: potential countermeasures for deep space exploration missions. Front Immunol. 2018;9:1437.
  32. Feuerecker M, Crucian BE, Quintens R, et al. Immune sensitization during 1 year in the Antarctic high-altitude Concordia environment. Allergy. 2019;74(1):64-77.
  33. Thornton LM, Andersen BL. Psychoneuroimmunology examined: The role of subjective stress. Cellscience. 2006;2(4):66-91.
  34. Rosenkranz MA, Davidson RJ, Maccoon DG, et al. A Comparison of Mindfulness-Based Stress Reduction and an Active Control in Modulation of Neurogenic Inflammation. Brain Behav Immun.2013 Jan;27(1):174-84.

 

Chapter 4

CBD’s Role in A Healthy Pain Response

 

The statements mentioned in this content have not been evaluated by the FDA, and are not intended to prevent, diagnosis, or treat any disease. Always work with your personal healthcare provider.

 

One of the most common reasons patients seek medical care is due to pain. I know this from personal experience as a large number of patients who visit my clinical practice are in pain.  Approximately 40% of adults in the United States are suffering from chronic pain, with an estimated annual cost of up to $635 billion.1 Being in pain can significantly damage your quality of life and interfere with both physical and mental activities. You often are unable to do the things you love to do and your work productivity may suffer. Conventional medicine’s answer to pain is often a prescription to opioid drugs. In chapter 2 of this book, I briefly touched upon the dangers of opioid side effects and addiction.

 

By contrast, phytocannabinoids like CBD are safer and aren’t addictive. The CB1 receptor is found throughout many areas of the body but its expression is weak in brain stem regions that control respiration. Since cannabinoids work through this receptor, the potentially fatal respiratory depression that occurs with opioid drugs does not occur with cannabinoids.2 Cannabinoids like CBD also reduce opioid tolerance and dependence.3

 

New research indicates that CBD actually allows people to eliminate or reduce their use of opioids. In an eight-week study, researchers investigated 97 patients between 30 and 65 years old who suffered from chronic pain who had been on opioids for at least one year.4 More than half of the chronic pain patients (53%) reduced or eliminated opioid use within eight weeks after beginning supplementation with CBD-rich hemp extract. Quality of life improved in nearly all CBD users (94%). The participants taking the CBD-rich hemp extract experienced significantly improved sleep and reduced pain severity. Unlike opioids, CBD is not addictive and is therefore a safer alternative.5

 

CBD and Joint Pain

 

Osteoarthritis (OA) is a disease that leads to joint degeneration, intermittent inflammation, and peripheral neuropathy (nerve pain). There’s a lot of logical reasons why CBD would be effective for sore, stiff joints. For example, receptors responsive to cannabinoids, including  CB1, CB2, GPR55, PPARα, and PPARγ, are located on human joint cartilage from people who have osteoarthritis symptoms.6 Cartilage cells from OA-affected joints express a wide range of cannabinoid receptors.6 This suggests that cartilage cells can respond to cannabinoids like CBD. What’s more, osteoarthritis leads to a combination of inflammatory, nociceptive, and neuropathic pain.7 Most pain is nociceptive pain. It refers to the type of pain that results from injury to body tissues. The endocannabinoid system reduces nociceptive as well as the other two types of OA-related pain.7

 

A number of animal studies have investigated the role of CBD in managing pain from osteoarthritis and rheumatoid arthritis. In one of these studies, researchers investigated whether CBD could relieve osteoarthritis-related pain.8 They also studied whether CBD could support a healthy inflammatory response and stop the development of OA-related pain and joint neuropathy. The scientists induced OA in male rats and then observed the effects of injecting CBD into the animals’ joints. In end-stage OA, CBD dose-dependently improved measures of joint health. CBD also reduced transient joint inflammation.  Prophylactic administration of CBD before the disease was at its worst stopped the development of later joint pain and protected nerve health. The researchers concluded, “These findings suggest that CBD may be a safe, useful therapeutic for treating OA joint neuropathic pain.”

 

Additional research strongly suggests CBD has a role to play in supporting joint health during rheumatoid arthritis. In an animal model of rheumatoid arthritis, CBD injected at 5 mg/kg per day or 25 mg/kg per day orally led to clinical improvement and protection against severe joint damage.9 It also supported healthy levels of inflammatory markers both in cell culture and in mice. According to the scientists, “Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect” in an animal model of rheumatoid arthritis.

 

CBD and Nerve Pain

 

Neuropathic pain is a form of chronic pain that occurs due to damage to the central or peripheral nervous systems. This type of pain is caused by physical trauma such as from accidents, surgery, or stroke, diseases like diabetes, cancer, and immune conditions, and certain medications such as cancer chemotherapy drugs. It is a severe, abnormal pain that often is triggered even when there is no stimulus or in the presence of normally harmless stimuli such as a light touch or stroking (like that which occurs when putting on clothing). Mild temperature changes, such as those that occur when you shower, can also trigger a painful response. Neuropathic pain is also linked to accompanying mental disturbances such as depression, anxiety, sleep problems, and less social interactions with family and friends.

 

Standard pharmaceuticals used for neuropathic pain are not always effective. At least half of people who suffer from this type of pain don’t experience meaningful pain relief after taking these medications.1 Furthermore, the drugs often produce severe side effects such as dizziness, sedation, depression, and sleep disorders.1 Consequently, many people find them intolerable.

 

In many studies of neuropathic pain in rodents, CBD had a beneficial effect. For example, mice were given a chemotherapy agent known to cause neuropathic pain.10 Cannabidiol injected into the abdomen of the animals before the chemotherapy agent reduced (but didn’t prevent) the chemotherapy-induced neuropathy. After CBD, the mice’s hind paws were less painful after pressure was administered.

 

In another study, researchers investigated CBD’s effects on neuropathic pain caused by sciatic nerve injury or inflammation in rats.11 Giving the rats CBD orally from day seven to two weeks after onset of the injury or inflammation decreased the increased sensitivity to pain after exposure to heat and touch.

 

Additionally, other researchers administered moderately high doses of intranasal cannabidiol in one group of mice and injected cannabidiol into the abdominal area of another group mice (intraperitoneal administration).12 At the same time, the scientists induced type 1 diabetes in the animals. Both the intranasal cannabidiol and intraperitoneal cannabidiol reduced the development of peripheral neuropathic pain. The pain reduction continued even after cannabidiol was discontinued and without any improvement in diabetes in the animals.

 

THC, the psychoactive component of cannabis, may be more effective at relieving pain compared with CBD.1 However, CBD can be used in higher doses compared with THC since it does not produce the high that THC does.1 This gives CBD an advantage over THC.

 

Most of the clinical research on CBD and neuropathic pain used a combination of both CBD and THC.13-15 Despite the lack of human studies focusing on CBD-use alone in neuropathic pain, there’s a lot of evidence from preclinical animal studies showing its effectiveness.5 What’s more, as mentioned earlier in the chapter, CBD use can help people wean off of opioids and isn’t addictive. This indicates CBD is a preferable option to many pain relievers.

 

CBD May Soothe Muscle Pain

 

Approximately 10% of the population suffers from widespread musculoskeletal pain.16 This group includes the 2% to 4% of the population that has fibromyalgia.17 People in pain frequently use marijuana or other products containing THC and CBD. The National Pain Report, a survey of 1,300 people, compared three regulatory body-approved pharmaceutical fibromyalgia treatments with cannabis.18 In regards to effectiveness of the treatments, the survey respondents strongly preferred cannabis over the prescription medicines.

 

CBD alone without THC may have a role to play in supporting the health of people with muscle and musculoskeletal pain. In a rat study, researchers used intramuscular injections of CBD and the mildly psychoactive cannabinoid cannabinol (CBN), alone and both combined to determine whether they could decrease muscle pain in the animals.19 CBD or CBN each decreased muscle pain. When used together, there was longer-lasting pain reduction compared to when each was used separately. However, CBN, as a breakdown product of THC, is mildly psychoactive and therefore many people may be reluctant to use it. This study showed that CBD does have a pain-reducing effect on its own and that CBD or CBD combined with CBN “may provide analgesic relief for chronic muscle pain disorders such as temporomandibular disorders and fibromyalgia without central side effects.”

 

In Chapter 1, I discussed a substance known as palmitoylethanolamide (PEA), which isn’t an endocannabinoid but works on the endocannabinoid system by helping the body make better use of the endocannabinoid AEA. In my patients suffering from pain, I often use both CBD and PEA for the best effects. PEA is able to reduce temporomandibular joint (TMJ) pain.20 It also can increase the effectiveness of standard fibromyalgia treatments.21

 

Visceral Pain and Irritable Bowel Syndrome

 

CBD may also reduce visceral pain, including pain involved in irritable bowel syndrome (IBS). Visceral pain affects the area surrounding the stomach, rectum, bladder, or uterus. An example is the abdominal pain that happens during IBS. Menstrual cramps and pelvic pain caused by bladder infections are other types of visceral pain.

 

CBD works through the endocannabinoid system, which regulates pain sensitivity caused by chronic stress.22,23 Changes to this system may be the reason why there’s a link between chronic stress and irritable bowel disease(IBD)/IBS.22,23 Research in rodents indicates stress during early life alters the endocannabinoid system, which increases the chances of developing IBS.24

 

Through its ability to regulate visceral pain, the endocannabinoid system may also be involved in the way in which psychological stress damages GI function. During stress, concentrations of the endocannabinoid anandamide decline while levels of the endocannabinoid 2-AG in the brain increase.25 By relieving stress, CBD may block stress-induced visceral pain. CBD benefits the hypothalamus-pituitary-adrenal (HPA) axis in mice exposed to psychological stress.26  The HPA axis controls the production of the stress hormone cortisol and is involved in the way the body handles stress. In addition, a number of human studies show CBD has a calming effect. I discussed these studies and other evidence of CBD’s stress-reducing properties in Chapter 2 of this book.

 

Headaches and Other Types of Pain

 

CBD may be able to reduce a variety of different kinds of pain. For example, there’s evidence it may reduce headaches and migraines.27 While there have been no clinical trials on the use of CBD and endometriosis, the endocannabinoid system is involved in regulating the pain that accompanies this condition.28 This suggests that CBD could play a role in supporting a healthy pain response in this disorder. In addition, cannabinoid-rich hemp oil reduced body pain and other symptoms in girls who reacted adversely to the human papillomavirus (HPV) vaccine.29 Furthermore, in seven kidney transplant patients, a group of patients who often experience pain, researchers gave the study subjects varying doses of CBD from 50 to 150 mg twice a day for three weeks.30 Two patients experienced complete improvement in pain, four experienced a partial improvement in the first 15 days, and one patient had no change.

 

How Cannabinoids Like CBD Reduce Pain – Mechanism of Action

 

CBD and cannabigerol (CBG) both have analgesic effects and their pain-relieving abilities may also be due to their ability to support a healthy inflammatory response.31

Endocannabinoids produced in the body can also block pain-inducing mechanisms in the gastrointestinal tract, the spine, and other areas of the body.32 This may lead to reducing pain in IBS, as well as from headaches, muscle spasms, and fibromyalgia.32 Deficiencies in endocannabinoids may lead to pain,32 and replenishing levels of these endocannabinoids through supplementation with CBD and other cannabinoids may help.

 

CBD’s potential ability to reduce pain may involve a type of receptor known as type 1 vanilloid receptor (TRPV1). Researchers have found the TRPV1 receptor in neurons that help regulate pain.33 I went into more detail about TRPV1 in Chapter one of this book.

CBD works in a way that’s different from substances like non-steroidal anti-inflammatory drugs (NSAIDS).  Unlike those drugs, it doesn’t inhibit the COX-1 enzymes.34,35 Blocking this enzyme is linked to gastrointestinal ulcers and bleeding. In addition, CBD doesn’t inhibit COX-2.34,35 Inhibition of this enzyme is associated with heart attacks and strokes.

 

The bottom line? Clinical experience, preclinical studies in animals, and some human studies show that CBD may support a healthy pain response. It’s non-addictive and isn’t psychoactive like THC. Therefore, I find it to be extremely clinically useful when dealing with my many patients who are suffering from pain.

 

 

  1. Casey SL, Vaughan CW. Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain. Medicines (Basel). 2018;5(3).
  2. Miller RJ, Miller RE. Is cannabis an effective treatment for joint pain? Clin Exp Rheumatol. 2017;35 Suppl 107(5):59-67.
  3. McCarberg BH. Cannabinoids:their role in pain and palliation. J Pain Palliat Care Pharmacother. 2007;21(3):19-28.
  4. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56-61.
  5. VanDolah HJ, Bauer BA, Mauck KF. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019;94(9):1840-1851.
  6. Dunn SL, Wilkinson JM, Crawford A, Bunning RAD, Le Maitre CL. Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies. Cannabis Cannabinoid Res. 2016;1(1):3-15.
  7. O’Brien M, McDougall JJ. Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids. Curr Opin Pharmacol. 2018;40:104-109.
  8. Philpott HT, OʼBrien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442-2451.
  9. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561-9566.
  10. Harris HM, Sufka KJ, Gul W, ElSohly MA. Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice. Planta Med. 2016;82(13):1169-1172.
  11. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007;556(1-3):75-83.
  12. Toth CC, Jedrzejewski NM, Ellis CL, Frey WH, 2nd. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain. 2010;6:16.
  13. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47(1):166-173.
  14. Hoggart B, Ratcliffe S, Ehler E, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol. 2015;262(1):27-40.
  15. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299-306.
  16. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol. 2003;17(4):547-561.
  17. Stensson N, Ghafouri B, Ghafouri N, Gerdle B. High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. Mol Pain. 2016;12.
  18. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-165.
  19. Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019;104:33-39.
  20. Hugger A, Schindler HJ, Türp JC, Hugger S. [Pharmacological therapy of temporomandibular joint pain]. Z Evid Fortbild Qual Gesundhwes. 2013;107(4-5):302-308.
  21. Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies. Pain Ther. 2015;4(2):169-178.
  22. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126(1):21-38.
  23. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol. 2007;7(6):575-582.
  24. Marco EM, Echeverry-Alzate V, López-Moreno JA, Giné E, Peñasco S, Viveros MP. Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. Behav Pharmacol. 2014;25(5-6):547-556.
  25. Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. 2016;41(1):80-102.
  26. Viudez-Martínez A, García-Gutiérrez MS, Manzanares J. Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress. J Psychopharmacol. 2018;32(12):1379-1384.
  27. Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache. 2018;58(7):1139-1186.
  28. Sanchez AM, Cioffi R, Viganò P, et al. Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis. Reprod Sci. 2016;23(8):1071-1079.
  29. Palmieri B, Laurino C, Vadalà M. Short-Term Efficacy of CBD-Enriched Hemp Oil in Girls with Dysautonomic Syndrome after Human Papillomavirus Vaccination. Isr Med Assoc J. 2017;19(2):79-84.
  30. Cuñetti L, Manzo L, Peyraube R, Arnaiz J, Curi L, Orihuela S. Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplant Proc. 2018;50(2):461-464.
  31. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60(6):1303-1314.
  32. Smith SC, Wagner MS. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2014;35(3):198-201.
  33. O’Hearn S, Diaz P, Wan BA, et al. Modulating the endocannabinoid pathway as treatment for peripheral neuropathic pain: a selected review of preclinical studies. Ann Palliat Med. 2017;6(Suppl 2):S209-s214.
  34. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4(1):245-259.
  35. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. Aaps j. 2009;11(1):109-119.

 

Chapter Five

 

Hemp-Oil Derived CBD Lifts Mood and Controls Addictions

 

The statements mentioned in this content have not been evaluated by the FDA, and are not intended to prevent, diagnosis, or treat any disease. Always work with your personal healthcare provider.

 

Depression is an all-too-common psychiatric disorder. An estimated  20% of people suffer from depression.1 Regularly feeling sad, empty, or losing interest or no longer taking pleasure in everyday activities (anhedonia) are some symptoms of depression. Not being able to concentrate or make decisions, insomnia, or feeling excessively sleepy during the day are also indications you or a loved one may be depressed.

 

Depression is also linked to addiction, as many depressed people turn to substance abuse as a way to try to make their bad feelings disappear. As many as 30% to 40% of individuals with a drug addiction also meet the criteria for depression or an anxiety disorder.2

The conventional treatment for depression is to prescribe antidepressant medications. However, many people don’t respond to these drugs or discontinue use due to side effects.3

How the Endocannabinoid System Boosts Mood

The endocannabinoid system is involved in keeping us in a happy state of mind. As a reminder, your body makes endocannabinoids called AEA and 2-AG. These endocannabinoids are part of the endocannabinoid system along with CB1 and CB2 cannabinoid receptors activated by AEA and 2-AG and enzymes responsible for the endocannabinoid’s breakdown. In animal research, a deficiency in endocannabinoids is linked to depression.4 In animal studies of depression and stress, 2-AG brain tissue concentrations and AEA levels are altered.4

A common way for researchers to study depression in rodents is to administer a forced swim test. It has been noted that antidepressant-like substances given to the rodents before the test will cause them to swim longer and harder. The animals not given any antidepressant will often stop making movements beyond those necessary to lift their heads above water. In one of these tests, the endocannabinoid AEA reduced the amount of time mice remained immobile.5

There’s also evidence in humans that when the endocannabinoid system isn’t working properly, it may result in depression. In postmortem studies of alcoholic suicide victims, higher than normal levels of endocannabioids were found in the dorsolateral prefrontal cortex area of the brain.6 The study authors suggested that these increases in endocannabinoid levels may cause emotional discomfort during depression and that alcoholic suicidal patients may have a hyperactive endocannabinoid system. They concluded that the endocannabinoid system, “may be a novel therapeutic target for the treatment of suicidal behavior.”

 

In addition, clinical trials of untreated depressed patients have observed a rise in serum AEA levels.7 Plus, there’s a link between higher endocannabinoid levels and higher blood pressure levels in depressed women.8 What’s more, female patients with major depression have lower levels of the endocannabinoid 2-AG.7  The clinical conclusion is that balance, sustaining a healthy promoting homeostasis, is essential to best control the impact of dysregulation of the endocannabinoid system as an exacerbating factor in mental health signs and symptoms.

CBD’s Role in Promoting A Happy Mood and Increased Motivation

Studies in animals and limited research in humans—as well as results doctors like myself are seeing in clinical practice—indicate CBD is a natural mood booster. In forced swim tests in mice, CBD caused the mice to swim longer and harder, an indication it was improving their mood and motivation.9 According to the study authors, “The data support a promising therapeutic profile for CBD as a new fast-acting antidepressant drug.”

In other rodent studies, CBD has produced similar results, decreasing immobility in the forced swim test and increasing the animals’ likelihood to explore a maze and novel objects.10,11 This suggests CBD can improve feelings of hopelessness and maintain pleasure felt while participating in daily activities.

Despite reports from many physicians who are giving CBD to depressed patients with good results, human trials using CBD in depression are lacking. However, as I reported in Chapter 3 of this book, there are a number of human studies showing CBD can reduce stress. Ongoing stress is known to trigger depression and CBD’s ability to soothe stressful feelings may be the reason why there are many reports of it being a natural mood booster.

There are many other logical ways in which CBD could improve mood, some of them related to the means by which CBD reduces stress. These have all been demonstrated in rat studies. First, CBD triggers hippocampal neurogenesis, the birth of new neurons in the hippocampus.12 Long-term stress as well as depression can reduce hippocampal neurogenesis, but CBD has a protective effect.13 This all comes back to the endocannabinoid system, as the means by which CBD triggers this neurogenesis depends on there being present high enough levels of the endocannabinoid AEA.14 In patients with minor depression, AEA levels were higher compared with controls, suggesting that AEA is neuroprotective in patients with less severe depression.14

CBD also acts on the serotonin (5-HT1A) receptor.14 Serotonin is a neurotransmitter involved in feelings of well-being and happiness. Plus, in animal research, CBD elevates levels of brain-derived neurotrophic factor (BDNF), which is involved in the survival of nerve cells.9 Low levels of BDNF are associated with major depressive disorder in humans.15

Another way in which CBD increases feelings of well-being is by blocking the enzyme FAAH, which, as I mentioned in Chapter 1, breaks down the endocannabinoid AEA. By blocking FAAH, CBD increases levels of AEA, which is also known as the “bliss molecule” since it promotes feelings of happiness.

 

CBD and Addictions

 

CBD is one of the most useful tools I’ve used in my clinical practice in helping patients who suffer from addictions, whether it’s to alcohol, drugs, or cigarettes. As I mentioned earlier in this chapter, people who suffer from addictions often also suffer from depression. And chronic stress can be a trigger for addicts to turn to drugs or alcohol. After a period of withdrawal, the willpower to avoid a relapse in drug use is one of the biggest challenges in the treatment of addiction. CBD’s ability to boost mood and soothe away stress can be extremely beneficial in helping people with addictions avoid drugs, alcohol, and tobacco.

 

Preclinical studies in animals and human trials have found that CBD reduces cravings. For example, a randomized, double blind placebo controlled study evaluated the use of cannabidiol (CBD) or a placebo in 24 smokers who wished to stop smoking.16 Half of the participants used an inhaler of CBD while the other half used a placebo whenever they felt the urge to smoke over the course of a week. There were no differences in the number of cigarettes smoked in smokers using the placebo inhaler. However, subjects using the CBD inhaler smoked approximately 40% fewer cigarettes.

 

CBD’s ability to reduce nicotine cravings is likely accomplished through its interactions with the endocannabinoid system, specifically its ability to block the enzyme FAAH and increase levels of the “bliss molecule” endocannabinoid AEA. Studies have shown that blocking FAAH stops nicotine cravings, as well as nicotine’s ability to produce dopamine and therefore its pleasurable effects.17,18 By blocking FAAH, CBD also reduces anxiety during nicotine withdrawal.19

 

CBD and Opioid Addiction

 

In Chapter 2, I briefly covered CBD’s possible role in solving the opioid addiction crisis. Opioid painkillers are highly addictive and lead to fatal overdoses. As I discussed in Chapter 2, every day, 128 people in the United States die from an opioid overdose. Receptors in the endocannabinoid system interact with opioid receptors.20 CBD works at least in part through the endocannabinoid system, so it makes sense that it has a role to play in stopping opioid addiction.

 

Withdrawal symptoms of drug use may include such symptoms as sleep disturbances, anxiety, unease or dissatisfaction (dysphoria), and fatigue. People withdrawing from drugs also are unable to handle stress and have recurrent intense cravings for the drug, which can last for months or years and lead to relapse.  Animal studies show CBD can stop opioid-drug seeking behavior and reduce withdrawal symptoms. For example, in one study, rats were able to avoid using heroin, an opioid drug, similar to the way that humans with addictions must exercise self-control to avoid relapsing.21

 

In addicts there are emotional events and triggers that lead to relapses and the researchers exposed the animals to similar triggers.21 Compared to a placebo control, CBD did not change the rats’ self-administration of heroin nor overall drug-seeking behavior. However, it reduced heroin-seeking behavior when the rats were exposed to a specific trigger cue. CBD stopped the animals from seeking out heroin even 24 hours and two weeks after the rats were given CBD.

In other rodent research, CBD and another phytocannabinoid cannabinol (CBN) were able to reduce withdrawal symptoms in animals addicted to morphine.22,23

Emerging evidence in humans has found similar results. In a double-blind study of heroin-addicted people who had not used the drug for seven days, participants were randomized to receive three consecutive days of CBD or placebo.24 The study found that a single administration of CBD reduced drug cravings caused by typical triggers immediately after CBD use, 24 hours later, and even a week after the last dose was given. CBD also reduced anxiety while withdrawing from the heroin. The scientists believe their findings suggest that CBD is likely to prevent a relapse.

A case study nicely demonstrates how CBD can be used in people with both depression and addictions.25 The case study was of a young patient with multiple substance use disorder including cannabis, cocaine, and ecstasy combined with severe depression, social phobia, and narcissistic personality disorder. After antidepressant medications didn’t work, the researchers administered CBD capsules in increasing dosages (100 mg to 600 mg over eight weeks). CBD was safe and well tolerated. What’s more, after treatment with CBD, the patient’s depression improved as well as anxiety symptoms such as phobias, paranoia, and dissociation (feeling disconnected from thoughts, feelings, and memories). The patient stopped using addictive drugs including THC (marijuana) without showing withdrawal symptoms.

 

CBD’s Role in Cocaine Addiction and Alcoholism

In some rodent studies, CBD hasn’t been as beneficial in cocaine withdrawal and relapse.26,27 However, in other rodent studies, it has reduced intake of cocaine and blocked the liver toxicity and seizures caused by cocaine.28,29 For alcohol withdrawal and long-term reduction of cravings, many doctors report it is effective, especially if combined with a full protocol of supplements that can help with withdrawal. Furthermore, in rodent studies, CBD reduced alcohol-seeking behavior that occurs after common triggers and stress.30 It also blocked convulsions caused by alcohol withdrawal.30 In addition, in both rodent and cell culture studies, CBD was neuroprotective after exposure to alcohol and reduced liver toxicity caused by alcohol.30

Clinical Considerations

It is essential to address nutritional, metabolic, endocrine, and lifestyle variables when assisting individuals with mood and addiction disorders.  One or more epigenetic factors can serve as impediments to successfully addressing the underlying physiological susceptibilities that have yielded the clinical presentation of altered neurochemistry.

 

 

References

 

  1. Scherma M, Masia P, Deidda M, Fratta W, Tanda G, Fadda P. New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. Medicines (Basel). 2018;5(4).
  2. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247-257.
  3. Han MH, Nestler EJ. Neural Substrates of Depression and Resilience. Neurotherapeutics. 2017;14(3):677-686.
  4. Smaga I, Bystrowska B, Gawliński D, Przegaliński E, Filip M. The endocannabinoid/endovanilloid system and depression. Curr Neuropharmacol. 2014;12(5):462-474.
  5. Umathe SN, Manna SS, Jain NS. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav Brain Res. 2011;223(1):125-134.
  6. Vinod KY, Arango V, Xie S, et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry. 2005;57(5):480-486.
  7. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41(2):48-53.
  8. Ho WS, Hill MN, Miller GE, Gorzalka BB, Hillard CJ. Serum contents of endocannabinoids are correlated with blood pressure in depressed women. Lipids Health Dis. 2012;11:32.
  9. Sales AJ, Fogaça MV, Sartim AG, et al. Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex. Mol Neurobiol. 2019;56(2):1070-1081.
  10. Shbiro L, Hen-Shoval D, Hazut N, et al. Effects of cannabidiol in males and females in two different rat models of depression. Physiol Behav. 2019;201:59-63.
  11. Shoval G, Shbiro L, Hershkovitz L, et al. Prohedonic Effect of Cannabidiol in a Rat Model of Depression. Neuropsychobiology. 2016;73(2):123-129.
  12. Campos AC, Fogaça MV, Scarante FF, et al. Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front Pharmacol. 2017;8:269.
  13. Campos AC, Ortega Z, Palazuelos J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol. 2013;16(6):1407-1419.
  14. Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17.
  15. Kerling A, Kück M, Tegtbur U, et al. Exercise increases serum brain-derived neurotrophic factor in patients with major depressive disorder. J Affect Disord. 2017;215:152-155.
  16. Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38(9):2433-2436.
  17. Forget B, Coen KM, Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration–comparison with CB(1) receptor blockade. Psychopharmacology (Berl). 2009;205(4):613-624.
  18. Scherma M, Panlilio LV, Fadda P, et al. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther. 2008;327(2):482-490.
  19. Cippitelli A, Astarita G, Duranti A, et al. Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS One. 2011;6(11):e28142.
  20. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):239-257.
  21. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009;29(47):14764-14769.
  22. Bhargava HN. Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology (Berl). 1976;49(3):267-270.
  23. Hine B, Torrelio M, Gershon S. Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. Res Commun Chem Pathol Pharmacol. 1975;12(1):185-188.
  24. Hurd YL, Yoon M, Manini AF, et al. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015;12(4):807-815.
  25. Laczkovics C, Kothgassner OD, Felnhofer A, Klier CM. Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Neuropsychiatr. 2020.
  26. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl). 2004;175(3):360-366.
  27. Mahmud A, Gallant S, Sedki F, D’Cunha T, Shalev U. Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats. J Psychopharmacol. 2017;31(1):96-104.
  28. Luján M, Castro-Zavala A, Alegre-Zurano L, Valverde O. Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus. Neuropharmacology. 2018;143:163-175.
  29. Vilela LR, Gomides LF, David BA, et al. Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. Mediators Inflamm. 2015;2015:523418.
  30. Turna J, Syan SK, Frey BN, et al. Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. Alcohol Clin Exp Res. 2019;43(4):550-563.

 

Chapter 6

 

Keeping Your Brain and Central Nervous System Healthy

 

The statements mentioned in this content have not been evaluated by the FDA, and are not intended to prevent, diagnosis, or treat any disease. Always work with your personal healthcare provider. 

 

There’s a lot of evidence building up in the medical literature to show cannabidiol and other cannabinoids like CBG protect the brain. They can do this in a number of ways, including acting as antioxidants and reducing neuroinflammation.1 This means they’re useful in supporting the health of patients with Alzheimer’s disease, Huntington’s, Parkinson’s, autism, ADHD, epilepsy, schizophrenia, and multiple sclerosis. In this chapter, I’ll talk about how CBD and other cannabinoids can promote neurological health and keep your brain healthy and strong now and throughout your golden years. CBD and phytocannabinoids found in hemp oil may be the solution to keep your independence as you age.

 

Alzheimer’s

 

Alzheimer’s disease (AD) is a neurodegenerative disease that is the most common form of dementia, responsible for more than 60% of cases.2 Worldwide, 33 million people suffer from this debilitating illness.2 Alzheimer’s disease is characterized by cognitive decline caused by the buildup of amyloid beta (Aβ) proteins. These sticky proteins disrupt communication between brain cells and activate immune cells. The activated immune cells trigger inflammation. In turn, brain cells are destroyed. Cell culture studies have shown CBD can protect against neurotoxicity caused by Aβ.2

 

Inflammation that occurs in the brain and central nervous system (CNS) is called neuroinflammation. Cells in the CNS known as astrocytes keep this important bodily system balanced by recycling of neurotransmitters and providing nutrients to neurons. Any injury to the CNS can lead to changes in these astrocytes. These changes are what scientists call reactive gliosis. CBD can reduce reactive gliosis and neuroinflammation to encourage neurogenesis, the creation of new brain cells.2

 

In cell culture studies, CBD protects neurons, blocks the degeneration of brain cells, and controls the migration of immune cells known as microglia.2 Microglial activation is toxic to the brain and CBD protects against this neurotoxicity.2 In vitro, CBD also reduces tau overexpression.2 Like amyloid beta, tau is a protein that accumulates in the brain. It has some beneficial effects, but it can form clumps of toxic neurofibrillary tangles, which lead to the neurodegeneration of Alzheimer’s.

 

In rodent models of Alzheimer’s, CBD reverses and stops cognitive dysfunction.2,3 Other rodent models of Alzheimer’s disease have found CBD promotes a healthy inflammatory response.4 It’s also neuroprotective.4 For example, in a mouse model of AD, the scientists injected the animals with human amyloid beta and then treated the animals daily with abdominal injections of CBD for a week.4 CBD suppressed a marker of activated astrocytes that is one of the main features of reactive gliosis caused by the buildup of amyloid beta. The results suggested CBD reduced damage caused by Aβ. Other animal research shows CBD can block the gliosis and neuroinflammation linked to Alzheimer’s.5

It also promotes neurogenesis.5

Most impressively, researchers induced Alzheimer’s in mice by injecting the animals with Aβ. CBD injections for 1 week and then 3 times/week for the following 2 weeks improved cognition.3 The researchers measured the spatial learning of the mice by having them try to navigate the Morris Water Maze. Spatial learning refers to the ability to find your way in and around your surroundings. CBD treatment reversed the cognitive problems that occurred in the mice injected with Aβ and improved spatial learning in the animals.

In a mouse model of genetic Alzheimer’s, animals were treated for three weeks with injections of CBD after they developed cognitive problems and signs of AD pathology in their brains.6 CBD reversed the cognitive declines in two types of memory: object recognition and social recognition.

 

Unfortunately, despite a lot of evidence from preclinical animal studies showing CBD may have a role to play in supporting the health of Alzheimer’s patients, to my knowledge there haven’t been any human studies of CBD in AD. Hopefully, based on all the promising preclinical evidence, scientists will soon study CBD’s effects in this group of people.

 

Parkinson’s Disease

Parkinson’s disease (PD) is a common neurodegenerative disorder. Its prevalence increases with age, with 1% of the population over 60 years old suffering from the disorder.7 There are two primary characteristics of the disease. First, there’s what scientists call motor impairment which includes hypokinesia (slow movement), tremors, and muscle rigidity. Second, people with PD have non-motor symptoms such as sleep disturbances, cognitive problems, anxiety, depression, and psychotic symptoms. These problems are caused by the destruction of neurons that produce the brain chemical dopamine. This leads to low levels of dopamine, an important neurotransmitter involved in feeling pleasure, thinking, planning, and focusing.

Several human studies show CBD may have some impressive benefits in people with PD. In one of those studies, researchers investigated the effects of CBD in six PD patients who had psychotic symptoms for at least three months.8 The patients received a flexible oral dose of CBD starting with 150 mg/day for four weeks combined with their standard therapy. After using CBD, the participants experienced a significant improvement in the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire. CBD also lowered the scores of the Unified Parkinson’s Disease Rating Scale, showing it could improve other aspects of the condition as well. CBD didn’t lead to any adverse effects. According to the researchers, “These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.”

 

In a double-blind study of 21 Parkinson’s patients without dementia or coexisting psychiatric conditions, the patients received either 75 mg or 300 mg/day CBD or a placebo.9 Although CBD did not lead to improvements in PD symptoms or neuroprotective effects, patients receiving 300 mg/day CBD were found to have a significantly better quality of life. The study authors believe this may have been due to CBD’s ability to calm the mind and boost mood along with its beneficial effects in psychosis.

Parkinson’s patients often experience a condition known as REM sleep behavior disorder (RBD).10 This condition is associated with vivid nightmares, and patients often act out their nightmares in their sleep, such as trying to run away from someone chasing them in their dreams. In a study of four PD patients, CBD quickly and significantly reduced the frequency of RBD-related problems without causing any side effects.10

The human studies conducted on CBD in PD showed that this phytocannabinoid may reduce non-movement-related symptoms of PD. However, in rodent models of PD, CBD has improved movement-related symptoms. For example, CBD stopped abnormal movements from occurring when rodents were given antipsychotic drugs known to cause rigidity of the body.11,12

 

One way in which CBD may benefit PD is through its ability to protect the mitochondria, the powerhouses of the cells.13 Research shows that when the mitochondria are not working properly it can lead to the development of PD.14

CBD increases mitochondrial activity.13 Furthermore, in rats exposed to iron overload, which resembles neurodegenerative disorders, CBD reverses the damage that excess iron does to mitochondrial DNA.15

 

Huntington’s Disease

 

Huntington’s disease is an inherited neurological disorder caused by a mutation in the gene encoding the protein huntingtin. It’s characterized by involuntary movements (chorea) and cognitive problems. There’s a lot of reasons why CBD and other phytocannabinoids could play a role in supporting health in Huntington’s disease. Research in animals shows that endocannabinoid system activity is significantly reduced in HD, often at the early stages of the disease.16,17

 

Studies in rodents also show CBD may keep brain cells healthy. In one study, researchers exposed striatal neurons—a type of brain cell affected in HD—to a mitochondrial toxin.18 This toxin causes changes similar to those that occur in HD. However, CBD protected the neurons from the toxin’s damaging effects. Many of the animal studies combined CBD with THC, the psychoactive component of marijuana. In these studies, the scientists gave the animals either the drug Sativex® which is a combination of CBD and THC or a similar combination of phytocannabinoids. In these studies, the CBD/THC combination protected the animals’ neurons.19,20

 

There aren’t a lot of studies in humans investigating whether CBD alone has a role to play in supporting the health of people with HD. In humans, researchers have studied CBD combined with THC in the drug Sativex® or synthetic cannabinoids. In HD, patients suffer from dystonia, involuntary muscle contractions leading to twitching or repetitive movements. One trial, which investigated several different types of pharmaceutical cannabinoids including Sativex® in seven HD patients, observed a lot of beneficial effects including improved motor skills and less dystonia.21 The CBD/THC combinations also improved the patients’ behavior. They were less irritable and apathetic. Plus, in some cases, they experienced less hypersalivation. Researchers are currently conducting a clinical trial of CBD combined with THC to see whether it can benefit people with HD. Results aren’t ready yet, but it will be interesting to see what the outcome will be.22

 

To my knowledge, there was only one small trial of 15 patients with HD who were given CBD alone rather than administering this phytocannabinoid together with THC.23 In this double-blind, randomized study the participants were given an average daily dose of about 700 mg/day for 6 weeks and then crossed over to a sesame oil placebo for six weeks. CBD was found to be safe, but it did not benefit the patients. A lot more studies need to be done before we can truly say whether CBD is effective.

 

It’s even entirely likely that when CBD is combined with other cannabinoids, such as in hemp oil, the hemptourage effect kicks in to produce better results. One review found that CBG, CBC, and CBDV were effective in rodent and cell culture models of HD.24 CBG blocked the loss of neurons caused by a toxin and reduced the activity of genes linked to HD. CBG also reduced inflammatory markers. Plus, HD-related problems with movement improved in rodents given CBG

 

Autism

 

Autism Spectrum Disorder (ASD) is characterized by poor social communication, restricted and repetitive patterns of behavior, interests, or activities, and intellectual disabilities. People with ASD also often suffer from coexisting conditions such as sleep problems, epilepsy, and attention deficit/hyperactivity disorder.

 

There’s good reason why CBD should support the health of people with ASD. The endocannabinoid system of ASD patients with seizures, anxiety, cognitive problems, and impaired sleep often isn’t working the way it’s supposed to.25

Additionally, compared with healthy controls, children with ASD have lower plasma levels of the body’s naturally produced endocannabinoid anandamide.26 These low anandamide levels are thought to play a role in problems that ASD patients have in social interactions with other people.27

 

There are many anecdotal reports that CBD works well in people with autism. Plus, as mentioned above, there’s strong justification why it would work in ASD. However, surprisingly, there aren’t a lot of studies backing up CBD’s use in ASD. Many of the studies that investigate CBD in autism used both CBD and THC. One study used cannabis with a high CBD content in 60 children with ASD who had severe behavioral problems.28 In 61% of the children given the CBD-rich cannabis, parents rated behavioral problems much improved or very much improved.

 

The justification behind using CBD alone in autism comes from studies that show this phytocannabinoid improves many symptoms that occur autism. These studies did not investigate CBD in autism directly but rather explored its use in problems common to ASD and other disorders. For example, as we’ve covered in previous chapters, CBD reduces stress and calms anxiety in people giving speeches. It also improves sleep. In animal studies of schizophrenia, CBD stopped social withdrawal and improved social interaction and cognition.29,30 In addition, in a mouse study of Dravet Syndrome (a severe type of epilepsy), both seizures and autism-like behaviors declined in the animals given CBD.31

 

Attention Deficit Hyperactivity Disorder

 

As the name of the disorder implies, people who have attention deficit/hyperactivity disorder (ADHD) have a hard time paying attention and are hyperactive. The disorder is also characterized by impulsiveness that interferes with a person’s ability to socialize or perform well at school or work. The Centers for Disease Control and Prevention estimates 6.1 million children and adolescents suffer from the disorder.32 An estimated 29.3% of children with ADHD will still have the condition when they become adults.33

 

The neurotransmitter dopamine doesn’t send the messages it’s supposed to in people with ADHD. Normally, dopamine acts on CB1 receptors in the endocannabinoid system. When dopamine doesn’t regulate the endocannabinoid system the way it should, it can lead to hyperactivity.34

 

Much of the basis for using CBD in ADHD comes from studies where the phytocannabinoid improved symptoms similar to those suffered by ADHD patients, although the studies weren’t done in people suffering from ADHD. In previous chapters I discussed CBD’s ability to calm anxious feelings in people giving a speech, and earlier in this chapter I talked about CBD’s ability to improve sleep in PD patients. Researchers have studied CBD in combination with THC (Sativex®) in 30 adults with ADHD.35 In this randomized, controlled study, cognitive performance didn’t improve, but hyperactivity, impulsivity, and measures of inhibition were significantly better. A rodent study using CBD without THC also showed promise. In this study, CBD stopped hyperactivity and social withdrawal.36

 

Epilepsy

 

Past animal studies and clinical trials have found that CBD can reduce seizures in a number of different types of epilepsy. For example, in a randomized, double-blind, placebo-controlled 14-week study of Dravet syndrome patients, CBD combined with anti-epileptic drugs led to more pronounced reductions in the frequency of convulsive seizures compared with a placebo.37

 

In another study, researchers investigated the effects of either a placebo or cannabidiol together with standard antiepileptic medication in 225 patients with a severe type of epilepsy (Lennox-Gastaut syndrome).38 In the double-blind, placebo-controlled trial, the subjects were divided into three groups that received either 20 mg per kilogram of body weight of a cannabidiol oral solution or 10 mg per kilogram or a matching placebo, given in two equally divided doses daily for 14 weeks. For 28 days before enrolling in the trial, all of the patients in the study had two or more drop seizures per week. Drop seizures—also called atonic seizures—are those that cause a loss of muscle strength and usually cause the patient to fall.

During the treatment period, median drop seizure frequency was reduced by 41.9% in the 20-mg cannabidiol group, 37.2% in the 10-mg cannabidiol group, and only 17.2% in the placebo group. There were mild adverse events in some of the patients, primarily those taking the highest dose, including sleepiness, decreased appetite, and diarrhea. Six patients in the 20-mg cannabidiol group and 1 patient in the 10-mg cannabidiol group discontinued the trial due to these effects. Liver enzymes were elevated in 14 patients who received CBD.

According to the study authors, “Among children and adults with the Lennox-Gastaut syndrome, the addition of cannabidiol at a dose of 10 mg or 20 mg per kilogram per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo.”

Many of the more recent studies have used a highly purified form of CBD known as Epidiolex®. In one of these studies, children and adults with treatment-resistant Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) who were also taking anti-epileptic drugs were given Epidiolex® in oral solution.39 At the study’s start, parents and caregivers kept a record of  the types and number of seizures experienced. The patients were started out at a dose of 2-10 mg/kg/day. Their dose was then gradually increased up to a maximum dose of 25-50 mg/kg/day. At 12 weeks, CBD use was associated with a 50% reduction in median monthly major motor seizures and a 44% reduction in total seizures. Consistent reductions in both seizure types occurred through 96 weeks. A complete resolution of seizures occurred in 5% of the participants. CBD was safe, although minor adverse events like sleepiness occurred in 30% of the study subjects and 24% suffered from diarrhea. When the researchers followed up with the patients in two years, the Improvements remained.

 

The researchers concluded, “Overall, these results support previous observational and clinical trial data showing that add-on CBD may be an effective long-term treatment option for patients with LGS or DS.”

 

Schizophrenia

 

Schizophrenia is a disorder characterized by hallucinations, social withdrawal, and lack of motivation. It occurs in 1% of the population, but is more common in people with close relatives who had the disorder. While not traditionally considered a neurological disorder, recent evidence from scientific journals suggests that this disease may belong under that classification. For example, scientists have found that gene mutations in schizophrenia interfere with excitatory and inhibitory neurotransmission.40 In other words, signals broadcast by brain chemicals are disrupted in this disease, leading to problems with brain function.

 

Studies have shown that an imbalanced endocannabinoid system is involved in schizophrenia. Levels of anandamide—an endocannabinoid naturally produced in the human body—are too low in people with psychotic symptoms.41 A double-blind, randomized, clinical trial showed what happens when CBD is given to schizophrenic patients with low anandamide.41 In 42 patients with schizophrenia, CBD was used at a dose of 200 mg per day to start and then increased by 200 mg per day until a daily dose of 200 mg four times daily (total 800 mg per day) was reached within the first week.41 CBD significantly increased serum anandamide levels. This increase in anandamide was linked to clinical improvement.

 

Although CBD hasn’t been found effective in all studies on its use in schizophrenia,42 there is still a lot of reason to believe CBD may have a role to play in the disorder. For example, in an exploratory double-blind trial, researchers randomized 88 patients with schizophrenia to receive either 1,000 mg/day of CBD or a placebo along with the antipsychotic medications the patients were already taking.43 After six weeks, patients taking CBD had less psychotic symptoms such as hallucinations compared to the placebo. In addition, the treating physicians of participants in the CBD group were more likely to rate the patients as improved and as “not severely unwell.” Patients given the CBD also experienced improvements in cognitive performance and overall functioning, although these improvements didn’t reach statistical significance. The patients tolerated the CBD well and adverse events occurred at a similar rate in both the CBD and placebo groups.

 

Multiple Sclerosis

 

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease associated with muscle stiffness, spasms, pain, and tremor. Nearly 1 million people in the United States suffer from this disorder, according to a study by the National Multiple Sclerosis Society.44

The endocannabinoid system regulates the muscle spasms that occur in MS.45 In an experimental study of MS and of MS tissue, local changes occurred in the endocannabinoid system in areas of MS lesions.45 In addition, the endocannabinoid system controls the amount of neurodegeneration that occurs due to inflammation.45

 

This is the reason why scientists started studying CBD together with THC in multiple sclerosis. The study results have been so promising that CBD plus THC in Sativex® is an approved anti-inflammatory drug treatment against spasms in multiple sclerosis.2,46,47 Some studies also suggest a CBD/THC combination may improve neuropathic pain in people with MS.48

 

Other phytocannabinoids like CBG may also help people with MS. A review of the medical literature found that CBG reduced activity of the proinflammatory oxidative enzyme myeloperoxidase (MPO) in a rodent study.49 Even though this study was done in animals with colitis, MPO is involved in other diseases such as multiple sclerosis.49

References:

 

  1. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95(14):8268-8273.
  2. Watt G, Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Front Pharmacol. 2017;8:20.
  3. Martín-Moreno AM, Reigada D, Ramírez BG, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol Pharmacol. 2011;79(6):964-973.
  4. Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol. 2007;151(8):1272-1279.
  5. Esposito G, Scuderi C, Valenza M, et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One. 2011;6(12):e28668.
  6. Cheng D, Low JK, Logge W, Garner B, Karl T. Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice. Psychopharmacology (Berl). 2014;231(15):3009-3017.
  7. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901-905.
  8. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23(8):979-983.
  9. Chagas MH, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088-1098.
  10. Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564-566.
  11. Gomes FV, Del Bel EA, Guimarães FS. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:43-47.
  12. Peres FF, Levin R, Suiama MA, et al. Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. Front Pharmacol. 2016;7:343.
  13. Valvassori SS, Bavaresco DV, Scaini G, et al. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Braz J Psychiatry. 2013;35(4):380-386.
  14. Ammal Kaidery N, Thomas B. Current perspective of mitochondrial biology in Parkinson’s disease. Neurochem Int. 2018;117:91-113.
  15. da Silva VK, de Freitas BS, Dornelles VC, et al. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. Brain Res Bull. 2018;139:1-8.
  16. Lastres-Becker I, Berrendero F, Lucas JJ, et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease. Brain Res. 2002;929(2):236-242.
  17. Lastres-Becker I, Hansen HH, Berrendero F, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease. Synapse. 2002;44(1):23-35.
  18. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci. 2007;26(4):843-851.
  19. Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012;3(5):400-406.
  20. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J Neurosci Res. 2011;89(9):1509-1518.
  21. Saft C, von Hein SM, Lücke T, et al. Cannabinoids for Treatment of Dystonia in Huntington’s Disease. J Huntingtons Dis. 2018;7(2):167-173.
  22. J GdY. Phase II-clinical trial on neuroprotection with cannabinoids in Huntington’s disease (SAT-HD) EudraCT. In:2010-024227-24.
  23. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991;40(3):701-708.
  24. Stone NL, Murphy AJ, England TJ, O’Sullivan SE. A Systematic Review of Minor Phytocannabinoids with Promising Neuroprotective Potential. Br J Pharmacol. 2020.
  25. Zamberletti E, Gabaglio M, Parolaro D. The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. Int J Mol Sci. 2017;18(9).
  26. Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018;9:18.
  27. Wei D, Lee D, Cox CD, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A. 2015;112(45):14084-14089.
  28. Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study. J Autism Dev Disord. 2019;49(3):1284-1288.
  29. Gururajan A, Taylor DA, Malone DT. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav Brain Res. 2011;222(2):299-308.
  30. Osborne AL, Solowij N, Babic I, Huang XF, Weston-Green K. Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. Neuropsychopharmacology. 2017;42(7):1447-1457.
  31. Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2017;114(42):11229-11234.
  32. Control CfD. Data and Statistics about ADHD https://www.cdc.gov/ncbddd/adhd/data.html#ref. Accessed August 18, 2020.
  33. Barbaresi WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics. 2013;131(4):637-644.
  34. Castelli M, Federici M, Rossi S, et al. Loss of striatal cannabinoid CB1 receptor function in attention-deficit / hyperactivity disorder mice with point-mutation of the dopamine transporter. Eur J Neurosci. 2011;34(9):1369-1377.
  35. Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795-808.
  36. Gururajan A, Taylor DA, Malone DT. Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. J Psychopharmacol. 2012;26(10):1317-1332.
  37. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020.
  38. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018;378(20):1888-1897.
  39. Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20.
  40. Pocklington AJ, Rees E, Walters JT, et al. Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia. Neuron. 2015;86(5):1203-1214.
  41. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e94.
  42. Boggs DL, Surti T, Gupta A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018;235(7):1923-1932.
  43. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2018;175(3):225-231.
  44. Society NMS. https://www.nationalmssociety.org/What-is-MS/How-Many-People

Accessed August 18, 2020.

  1. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des. 2008;14(23):2326-2336.
  2. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451-459.
  3. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131.
  4. Russo M, Naro A, Leo A, et al. Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis. Pain Med. 2016;17(6):1145-1154.
  5. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett. 2008;444(2):195-198.